Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis
Obesity Science & Practice · 2026-06 · 12 (3)
DOI: 10.1002/osp4.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 16.06.2026. Verfasst von Donna H Ryan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pennington Biomedical Research Center Baton Rouge Louisiana USA. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
As patient response to obesity medication can vary, it is crucial to identify both those likely and unlikely to respond to treatment. This post hoc analysis aimed to examine predictive characteristics in patients who achieved weight—related targets with fixed‐dose, extended‐release combination of naltrexone and bupropion (NB‐ER).
Methods
This pooled analysis included patients from three Phase 3, placebo‐controlled COR trials (NCT00532779, NCT00567255, NCT00456521). The impact of baseline characteristics in predicting changes in weight‐related anthropometric targets at 56 weeks in those who completed treatment and were ≥ 90% adherent to NB‐ER was evaluated with univariable and multivariable analyses.
Results
Of the 1692 patients analyzed, similar proportions of patients receiving NB‐ER versus placebo were female and White. Among patients treated with NB‐ER with ≥ 90% adherence, 73.2% achieved ≥ 5% body weight (BW) reduction, 47.6% achieved ≥ 10% BW reduction, 27.8% achieved ≥ 15% BW reduction, 33.7% achieved target body mass index, and 23.7% achieved target waist circumference thresholds. Among the baseline characteristics assessed, female sex and White race most consistently predicted the likelihood of achieving the target outcomes.
Conclusion
Adherence to NB‐ER was associated with achieving anthropometric targets; however, the ability to predict a successful response in advance of NB‐ER treatment is still limited.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pennington Biomedical Research Center Baton Rouge Louisiana USA.
- knownwell Needham Massachusetts USA.
- Northwestern University Feinberg School of Medicine Chicago Illinois USA.
- University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA.
- Geisinger Commonwealth School of Medicine Danville Pennsylvania USA.
- Brigham and Women's Hospital Center for Weight Management and Wellness Boston Massachusetts USA.
ORCID-Profile: Angela Fitch, Robert F Kushner, Caroline M Apovian
Zitieren
APA
Ryan, D. H., Fitch, A., Kushner, R. F., Tronieri, J. S., Still, C. D., & Apovian, C. M. (2026). Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis. Obesity Science & Practice, 12(3). https://doi.org/10.1002/osp4.70159
Vancouver
Ryan DH, Fitch A, Kushner RF, Tronieri JS, Still CD, Apovian CM. Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis. Obesity Science & Practice. 2026;12(3). doi:10.1002/osp4.70159
BibTeX
@article{Ryan2026,
author = {Ryan, Donna H and Fitch, Angela and Kushner, Robert F and Tronieri, Jena S and Still, Christopher D and Apovian, Caroline M},
title = {Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {3},
doi = {10.1002/osp4.70159}
}
EUVIMED